cbte.Wer kennt sie???????? - 500 Beiträge pro Seite

[fonx]

Sieht doch nicht schlecht aus???????????? FONX (Dreimonatschart)

[fonx]

http://cdchart.innovative-software.com/_common/informer/lib/…

[fonx]

Sorry,wollte was anderes einfügen, FONX

[fonx]

http://quotes.barchart.com/texpert.asp?sym=cbte

[js200]

02/07/2003 (11:11 ET) VOLUME(-): CBTE Volume 72% > 20-adsv, Stock -18.86% - Knobias
02/05/2003 (13:11 ET) 52W HIGH: New 52-Wk High for CBTE @ $2.640 up47.49% - Knobias
02/05/2003 (10:21 ET) VOLUME(+): CBTE Volume 347% > 20-adsv, Stock +17.32% - Knobias
02/04/2003 (18:22 ET) VOLUME(+): CBTE Volume 4219% > 20-adsv, Stock +138.67% - Knobias
02/04/2003 (12:36 ET) CBTE Sees FY02 Loss of ($625K) on Gross Rev of $4.4M - Knobias

JS200

[js200]

Commonwealth Biotechnologies, Inc. Regains Nasdaq Market Cap Compliance; Threat of De-Listing Under Market Cap Compliance Rules Removed
Commonwealth Biotechnologies, Inc. Regains Nasdaq Market Cap Compliance; Threat of De-Listing Under Market Cap Compliance Rules Removed

BW2284 NOV 21,2002 8:00 PACIFIC 11:00 EASTERN



( BW)(VA-COMMONWEALTH)(CBTE) Commonwealth Biotechnologies, Inc. Regains Nasdaq Market Cap Compliance; Threat of De-Listing Under Market Cap Compliance Rules Removed

Business Editors, Health & Medical Writers
BIOWIRE2K

RICHMOND, Va.--(BUSINESS WIRE)--Nov. 21, 2002--CommonwealthBiotechnologies, Inc. (CBI) (NASDAQ SmallCap Market: CBTE), a lifesciences contract research organization and biotechnology company, hasreceived notification that it has met the conditions of complianceunder Nasdaq´s minimum market value rule ((Marketplace Rule4310(c)(7)).
On August 16, 2002 the company was notified of potentialde-listing if this rule was not complied with by November 14, 2002.
"This is extremely good news for the company and underscores andrewards investor confidence in CBI. While the return to compliance isobviously attributable to increased share price and a larger publicfloat, we believe that increases in both of those parameters are theresult of an investor base that recognizes the long term potential ofCBI," said Richard J. Freer, Ph.D., Chair and COO of the Company.

About CBI

Founded in 1992, CBI is located at 601 Biotech Drive, Richmond, VA23235 (1-800-735-9224). The company occupied its 32,000 square footfacility in December, 1998. CBI has provided comprehensive researchand development services to more than 2,500 private, government, andacademic customers in the global biotechnology industry. For moreinformation, visit CBI on the web at www.cbi-biotech.com.

Any statements contained in this release that relate to futureplans, events or performance are forward-looking statements thatinvolve risks and uncertainties as identified in the Company´s filingswith the Securities and Exchange Commission. Actual results, events orperformance may differ materially. Specifically, there can be noassurance that the Company will not fall out of compliance again withthe relevant NASDAQ listing rules. No statement herein should beconsidered an offer of any securities. Readers are cautioned not toplace undo reliance on these forward-looking statements, which speakonly as the date hereof. The Company undertakes no obligation topublicly release the results of any revisions to statements that maybe made to reflect the events or circumstances after the date hereofor to reflect the occurrence of unanticipated events.

--30--mh/ch* CONTACT: Commonwealth Biotechnologies, Inc. Dr. Robert B. Harris, 800/735-9224, Fax [phone] KEYWORD: VIRGINIA INDUSTRY KEYWORD: BIOTECHNOLOGY SOURCE: Commonwealth Biotechnologies, Inc.

(c) 2002 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.


JS200

[js200]

http://www.biosupplynet.com/cfdocs/products/prod_list.cfm?su…

JS200